New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

FDA pushes back review period for Provention Bio’s diabetes drug

Provention Bio will have to wait a little bit longer to see if the U.S. Food and Drug Administration will approve its diabetes prevention drug, teplizumab. On Thursday, the company announced the regulatory agency extended its review period by three months for the Biologics License Application (BLA) to Nov. 17.